Guanfacine extended release in two patients with pervasive developmental disorders

Journal of Child and Adolescent Psychopharmacology

Volumn 21, Issue 3, 2011, Pages 287-290

  Blankenship, Kelly ^a   Erickson, Craig A ^a   Stigler, Kimberly A ^a   Posey, David J ^a   McDougle, Christopher J ^a  

^a RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATOMOXETINE; GUANFACINE; METHYLPHENIDATE;

AGGRESSION; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; AUTISM; BLOOD PRESSURE; CASE REPORT; CHILD; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERACTIVITY; IMPULSIVENESS; IRRITABILITY; LETTER; MALE; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PRESCHOOL CHILD; SCHOOL CHILD; SEDATION; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; DELAYED-ACTION PREPARATIONS; FEMALE; GUANFACINE; HUMANS; MALE; TREATMENT OUTCOME;

EID: 79958807592     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2010.0057     Document Type: Letter

References (15)

1. Aman MG: Stimulant drug effects in developmental disorders and hyperactivity toward a resolution of disparate findings. J Autism Dev Disord 12:385-396, 1982.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
3. Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, Scherer N, for the SPD503 Study Group: A randomized, doubleblind, placebo-controlled study of guanfacine extended release in children and adolescents with Attention-Deficit/Hyperactivity Disorder. Pediatrics 121:e73-e84, 2008.
4. Conner D, Spencer T, Kratochvil C, López FA, Lyne A, Stat C, Tremblay G: Effects of guanfacine extended release on secondary measures in children with attention-deficit/hyperactivity disorder and oppositional symptoms. San Francisco, CA, Annual Meeting of the American Psychiatric Association; May 2009 (abstract).
5. Greenhill L, Beyer DH, Finkleson J, Shaffer D, Biederman J, Conners CK, Gillberg C, Huss M, Jensen P, Kennedy JL, Klein R, Rapoport J, Sagvolden T, Spencer T, Swanson JM, Volkow N: Guidelines and algorithms for the use of methylphenidate in children with Attention Deficit/Hyperactivity Disorder. J Atten Disord 6:S89-S100, 2002.
6. Handen BL, Sahl R, Hardan AY: Guanfacine in children with autism and/or intellectual disabilities. J Dev Behav Pediatr 29:303-308, 2008.
7. Lecavalier L: Behavioral and emotional problems in young people with pervasive developmental disorders: Relative prevalence, effects of subjects characteristics, and empirical classification. J Autism Dev Disord 36:1101-1114, 2006. (Pubitemid 46020362)
8. Leucht S, Engel RR: The relative sensitivity of the clinical global impressions scale and the brief psychiatric rating scale in antipsychotic drug trials. Neuropsychopharmacology 31:406-412, 2006. (Pubitemid 43113404)
9. Merck. Available at www.merck.com/mmpe/lexicomp/guanfacine .html (accessed May 28, 2010), 2010.
10. Posey DJ, McDougle CJ: Guanfacine and guanfacine extended release: Treatment for ADHD and related disorders. CNS Drug Rev 13:465-474, 2007. (Pubitemid 350233473)
11. Posey DJ, Puntney JI, Sasher TM, Kem DL, McDougle CJ: Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: A retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 14:233-241, 2004. (Pubitemid 38988789)
12. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 62:1266-1274, 2005.
13. Sallee FR: Guanfacine extended release for ADHD. Curr Psychiatry 9:49-60, 2009.
14. Sallee F, McGough J, Wigal T, Donahue J, Lyne A, Biederman J, for the SPD503 Study Group: Guanfacine extended release in children and adolescents with attention deficit hyperactivity disorder: A placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 48:155-165, 2009.
15. Scahill L, Aman MG, McDougle CJ, McCracken JT, Tierney E, Dziura J, Arnold LE, Posey D, Young C, Shah B, Ghuman J, Ritz L, Vitiello B: A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 16:589-598, 2006. (Pubitemid 44737213)